Pan­dem­ic fears force Chi­nese biotech to post­pone Hong Kong IPO meet­ings — Bloomberg

At the same time the coro­n­avirus out­break orig­i­nat­ing from Wuhan is boost­ing shares prices of a raft of (most­ly over­seas) drug­mak­ers, it ap­pears to have al­so forced at least one do­mes­tic biotech to slow down its IPO plans in Hong Kong.

In­no­Care Phar­ma — a Bei­jing-based com­pa­ny fo­cused on can­cer and au­toim­mune dis­eases with a lead drug now lined up at Chi­na’s reg­u­la­tor — has de­cid­ed to post­pone in­vestor meet­ings in­tend­ed to gauge de­mand for the HKEX list­ing, Bloomberg re­port­ed. Ac­cord­ing to anony­mous in­sid­ers, In­no­Care had planned to raise about $200 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER